Top-Line Results Look Good for Lilly Type 2 Diabetes Drug Dulaglutide

A A
Eli Lilly’s once-weekly Type 2 diabetes candidate dulaglutide met its primary endpoint for hemoglobin A1c reduction in top-line results from three studies.

To View This Article:

Login

Subscribe To Drug Industry Daily